Other languages Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
7.37 ^USD	+1.66%		+7.43%	-39.79%

01/04	Sector Update: Health Care Stocks Slide Late Afternoon	MT
01/04	Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Slide Late Afternoon	02/04
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03
Sector Update: Health Care Stocks Ease Late Afternoon	09/03
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	09/03
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	20/12
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	14/12
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	01/12
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	28/11
Sector Update: Health Care Stocks Rise Tuesday Afternoon	22/11
Sector Update: Health Care	22/11
Pulse Biosciences Files Premarket Notification to FDA for CellFX nsPFA Percutaneous Electrode	21/11
Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode	21/11
Pulse Biosciences Insider Bought Shares Worth $123,470, According to a Recent SEC Filing	21/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Other languages

Filters